Evidence map›Paper›PMID 40244386›Full record

ReviewInternational journal of molecular sciences2025

Sidransky Syndrome-

Majdolen Istaiti, Gilad Yahalom, Mikhal Cohen, Volha Skrahina, Aliaksandr Skrahin, Jan Lukas, Arndt Rolfs, Ari Zimran

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Majdolen IstaitiAgyany Pharma Ltd., Jerusalem 9695614, Israel.
Gilad YahalomDepartment of Neurology and Movement Disorders Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Mikhal CohenDepartment of Neurology and Movement Disorders Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0000-0002-0267-2658
Volha SkrahinaAgyany Pharma Ltd., Jerusalem 9695614, Israel.
Aliaksandr SkrahinAgyany Pharma Ltd., Jerusalem 9695614, Israel.
Jan LukasTranslational Neurodegeneration Section Albrecht Kossel, Department of Neurology, University Medical Center Rostock, 18147 Rostock, Germany.ORCID 0000-0002-8061-5798
Arndt RolfsAgyany Pharma Ltd., Jerusalem 9695614, Israel.
Ari ZimranAgyany Pharma Ltd., Jerusalem 9695614, Israel.ORCID 0000-0003-0077-8608

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sidransky syndrome represents a distinct variant of Parkinson's disease (PD) that is linked to pathogenic variants in the glucocerebrosidase (

Indexed as

GlucosylceramidaseParkinson DiseaseAmbroxolHumansMolecular Targeted TherapyAmbroxolGBA protein, humanGlucosylceramidaseAmbroxolGaucher diseaseGBA1-related Parkinson’s diseasegenetic testingpharmacological chaperonesSidransky syndrome

Identifiers

PMID40244386
PMCPMC11989370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.